Nov 25, 2008 - The U.S. FDA has granted SELZENTRY (maraviroc) approval for use in treatment-experienced adults with CCR5-tropic HIV-1 in combination with other antiretrovirals. SELZENTRY was originally granted accelerated conditional approval in August 2007 based on 24-week data from pivotal Phase 3 studies. SELZENTRY now becomes the latest fully approved treatment for HIV.
The details can be read here.
No comments:
Post a Comment